[gem_divider margin_top=»33″]
MOLECULES
[gem_divider margin_top=»33″]

A unique portfolio of natural psychotropic compounds

Relying on more than two years of third-party research and development, we have identified promising molecules to be used as pharmaceutical drugs (sole and combined)

[gem_divider margin_top=»33″]
[gem_divider margin_top=»10″]
[gem_divider margin_top=»33″]
[gem_divider margin_top=»33″]
Clinical Research
[gem_divider margin_top=»33″]

First controlled trial to test a psychedelic substance in treatment-resistant depression Completed in 2016 by Biomind’s Chief Scientific and Clinical Advisor PhD Draulio Barros de Araujo

This study supports the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to address treatment-resistant depression. This study is registered at http://clinicaltrials.gov (NCT02914769)

[gem_divider margin_top=»33″]

Dr. Draulio Barros de Araujo is a 1995 graduate of the University of Brasilia with a degree in physics, and he completed his Ph.D in physics applied to medicine and biology, working with functional neuroimaging tools, in 2002 at the University of Sao Paulo. From 2009 to present, Dr. Draulio has been a professor (associate) of neuroscience at the Brain Institute of the University of Rio Grande do Norte (UFRN) in Brazil. From 2017 to 2019 Dr. Draulio held the position of visiting scholar at the Department of Psychological and Brain Sciences of the University of California in United States.

Since 2006 Dr. Draulio’s research has focused on using functional neuroimaging methods (EEG and fMRI) to investigate the acute and lasting effects of the psychedelic Ayahuasca.

In 2016, Dr. Draulio completed the first controlled trial to test a psychedelic substance (ayahuasca) in treatment-resistance depression, the results of which support the safety and therapeutic value of ayahuasca to address treatment-resistant depression. This study is registered at http://clinical trials.gov (NCT02914769). Dr. Draulio’s trial was Sponsored by University of Sao Paulo and had, as a trial collaboration partner, UFRN, two of the most prestigious universities in Brazil.

[gem_divider margin_top=»33″]

A closer view of Biomind’s Chief Scientific and Clinical Advisor
PhD Draulio Barros de Araujo

[gem_youtube video_id=»Fbix5o4Zoqk»]

In addition to his role as a Professor of neuroscience at the Brain Institute UFRN, Dr. Draulio
has several publications based on psychedelics such as:

  • Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion (Nov 2012)
  • The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network (Feb 2015)
  • Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca (Nov 2016)
  • Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study (Jan 2016)
  • Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (Jun 2018)
  • Unveiling ayahuasca psychopharmacology: the accomplishments of Jordi Riba (1968-2020) (Sep 2020)
  • Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca (Jul 2020)
  • Characterizing complex networks using Entropy-degree diagrams: unveiling changes in functional brain connectivity induced by Ayahuasca (Sep 2018), l) Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls (May 2018), ll) A Single Dose Of Ayahuasca Modulates Salivary Cortisol In Treatment-Resistant Depression (Jan 2018)
  • Subacute effects of the psychedelic ayahuasca on the salience and default mode networks (Apr 2020)
  • d-Lysergic acid diethylamide has major potential as a cognitive enhancer (Dec 2019), j) The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial (Oct 2019)
  • Acute antidepressant effect of ayahuasca in juvenile non-human primate model of depression (Jan 2018)
  • Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT (Oct 2017)
  • Assessing the Psychedelic «After-Glow» in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities (Jun 2017)
  • Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N,N-dimethyltryptamine (Mar 2017)
  • Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics (Jul 2016)
  • Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans (Jan 2015)
  • The Therapeutic Potentials of Ayahuasca in the Treatment of Depression (Jan 2014)
[gem_divider margin_top=»33″]
[gem_fullwidth background_style=»no-repeat» background_position_vertical=»bottom» container=»1″ padding_top=»100″][gem_divider margin_top=»90″][gem_divider margin_top=»24″]

We develop the next generation of medicines for the XXI Century

Average life expectancy is 73.2 years and keeps rising, we live more but sacrificing quality of life.

Stress is becoming just another part of life, and it’s getting worse.

Increasingly more people have been bringing work laptops and projects home with them at the end of the day.

Checking emails before bed, looking at the news at all hours due to smartphones and social media, are big drivers of global stress across the board.

“Psychedelics are the healthiest pathway to reset our mind and prepare it for the new challenges humanity will be facing in the coming decades”

[gem_divider margin_top=»200″][/gem_fullwidth]
[gem_fullwidth background_style=»no-repeat» background_position_vertical=»bottom» container=»1″ padding_top=»100″][gem_divider margin_top=»90″]
contact us
[gem_divider margin_top=»24″]

[fc id=’1′][/fc]

[gem_divider margin_top=»200″][/gem_fullwidth]